Inactive Instrument

News AXIM Biotechnologies, Inc. Other OTC

Equities

AXIM

US05463V1008

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

AXIM Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 16	CI
VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024	Mar. 27	AQ
AXIM Biotechnologies, Inc. announced that it has received $0.814555 million in funding	Mar. 14	CI
AXIM® Biotechnologies’ Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation	Feb. 20	AQ
AXIM Biotechnologies, Inc Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation	Feb. 20	CI
AXIM Biotechnologies, Inc. announced that it expects to receive $0.75 million in funding from Medical Marijuana, Inc.	Dec. 25	CI
AXIM® Biotechnologies Partners With Leading Diagnostic Manufacturer Auer Precision to Scale Assay Production	Dec. 20	AQ
AXIM Biotechnologies, Inc. Partners With Auer Precision to Scale Assay Production	Dec. 20	CI
AXIM Biotechnologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 20	CI
AXIM® Biotechnologies Develops First Non-Invasive, Rapid, Point-of-Care, Diagnostic Test for Parkinson’s Disease	23-09-12	BU
AXIM Biotechnologies Develops First Non-Invasive, Rapid, Point-Of-Care, Diagnostic Test for Parkinson's Disease	23-09-12	CI
AXIM Biotechnologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-21	CI
AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test	23-08-01	BU
AXIM Biotechnologies, Inc. Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test	23-08-01	CI
AXIM Biotechnologies - Optometric Management, Perform a Pre-Fit Ocular Surface Evaluation	23-07-26	AQ
AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide	23-07-12	AQ
AXIM Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide	23-07-12	CI
AXIM Biotechnologies, Inc. announced that it has received $20 million in funding	23-05-31	CI
AXIM Biotechnologies Announces Over 40 Initial Clinic Commitments for Its Full Diagnostic Assay Platform Launch	23-05-24	AQ
AXIM® Biotechnologies Appoints Kurt Phinney as Chief Operating Officer to Drive Scaling and Optimization of Manufacturing Unit	23-05-23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News AXIM Biotechnologies, Inc. Other OTC

Equities

AXIM

US05463V1008

Summary

Filters